Top Biotech Stock to Buy in October

Bausch Health Companies (TSX:BHC)(NYSE:BHC) stock looks like a deep-value play for biotech seekers.

| More on:
Workers use a microscope to do medical research in a modern laboratory.

Source: Getty Images

September has never been a month to get excited about. It’s a month of pain, and this year investors felt the full force on their TFSAs (Tax-Free Savings Accounts) and RRSPs (Registered Retirement Savings Plans). Indeed, the S&P 500 dropped just shy of 10% in what was a swift downward move, dragging the U.S. indices to new lows not seen since June.

Where the bear market moves is anybody’s guess. With a recession on the way and growing fear that earnings will take a couple of steps backward, everyone seems to be trampling over one another to the exits before the next round of earnings come due. Indeed, things can always be better than expected, but with central banks flooring it when it comes to interest rates, it’s never been so hard to hit the buy button, especially now that buying the dip is punished with steep losses, rather than rewarded with huge gains.

Buying the dip has gotten harder

Indeed, going into 2022, a lot of us were conditioned to take advantage of any market spill. They were short-lived. With markets steadily taking the escalator down for around 10 months, dip buyers are starting to get exhausted. Eventually, markets will turn a corner, and they’ll regain confidence. However, given the bull traps (bear market rallies) we’ve seen this year (the June-August rally was the most painful to see falter!), chasing momentum now seems futile.

In any case, there are still ways to make money as we inch into a tough year. Specifically, the biotech and healthcare space may be ripe with opportunity for investors. Biotechs tend to be less correlated to the state of the economy at any given instance. Demand for health care tends to remain stable, whether or not there’s a negative sign in front of a nation’s GDP (gross domestic product) for a given quarter.

In this piece, we’ll check out one intriguing biotech stock that may be worth pursuing amid market-wide weakness.

Bausch: A biotech stock that’s down and out

Biotech plays on the Canadian stock market are few and far between. But there are some intriguing value options for investors willing to go against the grain. Enter Bausch Health Companies (TSX:BHC)(NYSE:BHC), which is fresh off a collapse of more than 75% year to date. The firm has been steadily chipping away at debt since its days as the infamous Valeant Pharmaceuticals.

Though spinoffs of Bausch + Lomb and Solta bode well for the balance sheet, it’s generic competition (think IBS drug Xifaxan) that could weigh heavily on sales and margins moving forward. In the face of such competitive headwinds, management has endured quite a shuffle. Undoubtedly, such major moves in the c-suite have made the haze of uncertainty that much thicker for investors.

There’s a lot of baggage at Bausch. But the valuation is compelling at $9 and change per share. The stock trades at just 0.3 times price to sales. A lot of the bad news (including generic competition) seems baked in here, especially after a weak second quarter that saw earnings per share fall short of estimates ($0.56 versus the $0.89 estimate).

The bottom line

Biotech investing isn’t easy. Booms and busts are typical in the industry based on what comes out of the drug pipeline. Bausch has gone bust amid its profound transformation. Though recent quarters were bleak, I think the multiple has come down by way too much. In a market headed south, I find it tough to believe that Bausch will be as influenced by broader exogenous events (think Fed meetings) over the next 18 months.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Investing

oil tank at night
Energy Stocks

3 Super-Cheap TSX Energy Stocks to Buy Right Now

Here are three top undervalued TSX energy stocks to play the next leg of the crude oil rally.

Read more »

Hand arranging wood block stacking as step stair with arrow up.

5 Growth Stocks to Buy Before the Bear Market Is Over

Now is a great time to pick up growth stocks that can see shares soar in the next few years,…

Read more »

clock time

Fresh Take: These 3 TSX Stocks Are Super-Timely Buys

Here are three discounted TSX stocks to buy before the market goes on a raging bull run.

Read more »

money cash dividends
Tech Stocks

The Best TSX Stocks to Invest $5,000 in Right Now

These Canadian stocks have the potential to beat the broader market averages in the long term and generate solid capital…

Read more »

Choice of fashion clothes of different colors on wooden hangers

2 Retail Stocks That Are Too Cheap to Ignore

Canadian retail stocks such as Aritzia and Lululemon Athletica are well poised to deliver market-beating returns to investors.

Read more »

A bull and bear face off.

2 Stocks That Could Do Even Better in a Recession

Dollarama (TSX:DOL) and North West Company (TSX:NWC) stock are top defensives to help you retain wealth in a bear market.

Read more »

grow dividends
Tech Stocks

3 Monster Stocks to Buy Without Hesitation

Are you looking for great stocks to buy today? Here are three monster stocks you should buy without hesitation!

Read more »

data analyze research
Dividend Stocks

TFSA: Invest $29,000 in These 3 Stocks and Earn $515 Each Month in Passive Income in 2023

The benefits of the TFSA can be leveraged to hold a basket of dividend stocks and generate a stream of…

Read more »